Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Listen in as an advanced heart failure specialist discusses patient selection and post-implant management, the implant procedure, patient care pathways, and how Duke has incorporated Barostim into their system.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
Diagnosing female patients with coronary artery disease (CAD) has many challenges. Join us to hear from three key opinion leaders as they present data and new case studies demonstrating these difficulties, and the guidelines and pathways that help with diagnosis and management of women with suspected CAD.
Most advancements in electrophysiology technology are small and incremental, but the experts at Texas Cardiac Arrhythmia Institute in Austin, TX, were quick to see distinct advantages when they started using the latest iteration of radio frequency ablation, the QDOT MICRO™ Catheter.
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Listen in as an advanced heart failure specialist discusses patient selection and post-implant management, the implant procedure, patient care pathways, and how Duke has incorporated Barostim into their system.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
Diagnosing female patients with coronary artery disease (CAD) has many challenges. Join us to hear from three key opinion leaders as they present data and new case studies demonstrating these difficulties, and the guidelines and pathways that help with diagnosis and management of women with suspected CAD.
Most advancements in electrophysiology technology are small and incremental, but the experts at Texas Cardiac Arrhythmia Institute in Austin, TX, were quick to see distinct advantages when they started using the latest iteration of radio frequency ablation, the QDOT MICRO™ Catheter.
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
If you’re looking to grow your CCTA program or start one, listen in. Learn from cardiology and radiology experts at Wellstar Health System who have built a successful CCTA program.
Listen in to this discussion on enhancing efficiency for cardiologists and care teams with an integrated imaging and patient data strategy. Enterprise imaging simplifies IT by consolidating multi-ology images with patient data and providing a single view of all patient information.
Listen in to this CEU webinar to gain a deeper understanding of how the technology of intravascular lithotripsy (IVL) works in order to code appropriately for peripheral and coronary IVL procedures. We dig into coding and billing specifics for hospitals, ambulatory surgery centers and physicians across all payor types. Make sure your team is aware of all the coding rules and updates for 2025. To get your CEU, take the quiz and download your certificate!
